Products for Research Use Only

Sucrose octasulfate

CAT: 0804-HY-137273ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-137273ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Sucrose octasulfate, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate can be used in the study of chronic wound healing[1][2][3].
CAS Number
57680-56-5
UNSPSC
12352005
Target
MMP; Somatostatin Receptor
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=S(OC[C@@]1([C@H]([C@@H]([C@H](O1)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)(O)=O
Molecular Formula
C12H22O35S8
Molecular Weight
982.80
References & Citations
[1]Edmonds M, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer) : an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6 (3) :186-196.|[2]Dissemond J, et al. Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden [Sucrose octasulfate-evidence in the treatment of chronic wounds]. Hautarzt. 2020 Oct;71 (10) :791-801. German. |[3]Lucey MR, et al. Sucrose octasulfate stimulates gastric somatostatin release. Am J Med. 1991 Aug 8;91 (2A) :52S-57S.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported